A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia

References

• Smolewski P, Witkowska M, Korycka-Wolowiec A. New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. ISRN Oncol. 2013;2013:740615.
   PubMedGoogle Scholar
• Smith EN, Ghia EM, DeBoever CM, et al. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015;5:e303.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Infections in patients with leukemia and lymphoma. Cancer Treat Res. 2014;161:319–349.
   PubMedGoogle Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–581.
   PubMed Web of Science ®Google Scholar
• Sampalo A, Brieva JA. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape. Leuk Lymphoma. 2002;43:881–884.
   PubMed Web of Science ®Google Scholar
• Francis S, Karanth M, Pratt G, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107:1023–1033.
   PubMed Web of Science ®Google Scholar
• Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87:49–62.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Siddiqui AK, Rossoff L, et al. Pulmonary complications in chronic lymphocytic leukemia. Cancer. 2003;98:1912–1917.
   PubMed Web of Science ®Google Scholar
• Bairey O, Goldschmidt N, Ruchlemer R, et al. Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study Group. Eur J Haematol. 2012;89:491–496.
   PubMed Web of Science ®Google Scholar
• Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol. 2009;147:444–449.
   PubMed Web of Science ®Google Scholar
• Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma. 1994;13:203–214.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cancer. Available from: http://www.who.int/cancer/en/. 24.11.2017.
   Google Scholar
• Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121:2883–2891.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Weinberg JB, Yoshizaki A, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 2013;27:170–182.
   PubMed Web of Science ®Google Scholar
• Cutucache CE. Tumor-induced host immunosuppression: special focus on CLL. Int Immunopharmacol. 2013;17:35–41.
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44:383–389.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, et al. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;51:1829–1836.
   Google Scholar
• Jadidi-Niaragh F, Mehdi Y, Memarian A, et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest. 2013;31:121–131.
   PubMed Web of Science ®Google Scholar
• Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2011;2011:96–103.
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256–263.
   PubMed Web of Science ®Google Scholar
• Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994;179:999–1004.
   PubMed Web of Science ®Google Scholar
• Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia. 1996;10:1509–1513.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23:145–153.
   PubMed Web of Science ®Google Scholar
• Itälä M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Hematol. 1996;57:46–53.
   PubMed Web of Science ®Google Scholar
• Zeya HI, Keku E, Richards F 2nd, et al. Monocyte and granulocyte defect in chronic lymphocytic leukemia. Am J Pathol. 1979;95:43–54.
   PubMed Web of Science ®Google Scholar
• Gribben JG. How I treat CLL up front. Blood. 2010;115:187–197.
   PubMed Web of Science ®Google Scholar
• Oscier D, Dearden C, Eren E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159:541–564.
   PubMed Web of Science ®Google Scholar
• Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:99–104.
   PubMed Web of Science ®Google Scholar
• Colovic N, Bogdanovic A, Martinovic-Cemerikic V, et al. Prognostic significance of serum immunoglobulins in B-chronic lymphocytic leukemia. Archive Oncol. 2001;9:79–82.
   Google Scholar
• Martinot M, Oswald L, Parisi E, et al. Immunoglobulin deficiency in patients with Streptococcus pneumoniae or Haemophilus influenzae invasive infections. Int J Infect Dis. 2014;19:79–84.
   PubMed Web of Science ®Google Scholar
• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2008;1:450–456.
   PubMedGoogle Scholar
• Andersen MA, Vojdeman FJ, Andersen MK, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016;57:1592–1599.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer. 1988;61:279–283.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427–2437.
   PubMed Web of Science ®Google Scholar
• Piper KP, Karanth M, McLarnon A, et al. Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin Exp Immunol. 2011;166:154–163.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Gross E, Kühlein E, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia. 2010;24:1310–1316.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma. 2009;9:365–370.
   PubMedGoogle Scholar
• Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:240–249.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001;19:3611–3621.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431–2448.
   PubMed Web of Science ®Google Scholar
• Chang JE, Kahl BS. Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother. 2012;13:1495–1505.
   PubMed Web of Science ®Google Scholar
• Carter SJ, Bernstein SH, Friedberg JW, et al. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res. 2011;35:e223–e224.
   PubMed Web of Science ®Google Scholar
• Rago A, Ridola L, Lichtner M, et al. Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. J Antimicrob Chemother. 2012;67:510–511.
   PubMed Web of Science ®Google Scholar
• Sutton E, Lopez JJ, Dao LN, et al. Disseminated herpes zoster in chronic lymphocytic leukemia. J Emerg Med. 2016;50:159–160.
   PubMed Web of Science ®Google Scholar
• Kemming JL, van Zeeland RE, Ullmann EF, et al. [Interstitial pneumonitis as a side effect of rituximab]. Ned Tijdschr Geneeskd. 2009;153:A526.
   PubMedGoogle Scholar
• Tapan U, May SK, Fiore J, et al. Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma. Leuk Lymphoma. 2011;52:916–918.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Klippstein A, Schneider CP, Sayer HG, et al. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol. 2003;129:316–319.
   PubMed Web of Science ®Google Scholar
• Cougoul P, Tournier E, Delavigne K, et al. Acquired epidermodysplasia verruciformis, a new opportunistic infection related to bendamustine. Ann Hematol. 2015;94:1071–1073.
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Hematol. 1993;50:292–296.
   PubMed Web of Science ®Google Scholar
• Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol. 1993;4:371–375.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49:135–142.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Kontoyiannis DP, O’Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559–566.
   PubMed Web of Science ®Google Scholar
• Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94:2033–2039.
   PubMed Web of Science ®Google Scholar
• Byrd JC, McGrail LH, Hospenthal DR, et al. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Brit J Hematol. 1999;105:445–447.
   PubMed Web of Science ®Google Scholar
• Smolej L. The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012;21:1009–1017.
   PubMed Web of Science ®Google Scholar
• Anaissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med. 1992;117:466–469.
   PubMed Web of Science ®Google Scholar
• MabCampath® Summary of Product Characteristics. Genzyme. 2012 [cited 2016 Jun]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000353/WC500025270.pdf
   Google Scholar
• Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004;18:484–490.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313–4320.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15:e2–e16.
   PubMed Web of Science ®Google Scholar
• Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924–2930.
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13:106–111.
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–4840.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Ogasawara R, Miyashita N, et al. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol. 2012;95:588–591.
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–1312.
   PubMed Web of Science ®Google Scholar
• Arzerra® Summary of Product Characteristics. Novartis. 2015 [cited 2016 Jun]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001131/WC500093091.pdf
   Google Scholar
• Gazyvaro® Summary of Product Characteristics. Roche. 2015 [cited 2016 Jun]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002799/WC500171594.pdf
   Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2549.
   PubMed Web of Science ®Google Scholar
• Imbruvica® Summary of Product Characteristics. Janssen. 2016 [cited 2016 Jun]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf
   Google Scholar
• Agency EM. EMA recommends new safety measures for Zydelig measures include close monitoring and use of antibiotics to prevent pneumonia. 2016:3.
   Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778.
   PubMed Web of Science ®Google Scholar
• Sandherr M, Einsele H, Hebart H, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol. 2006;17:1051–1059.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Bhadelia N, Poneros JM, et al. Visceral varicella in a patient with chronic lymphocytic leukemia treated with fludarabine: a case report. Clin Lymphoma Myeloma Leuk. 2013;13:90–92.
   PubMed Web of Science ®Google Scholar
• Melchardt T, Weiss L, Greil R, et al. Viral infections and their management in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1602–1613.
   PubMed Web of Science ®Google Scholar
• Giridhar KV, Shanafelt T, Tosh PK, et al. Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. Leuk Lymphoma. 2016;14:1–4.
   Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12:1204–1213.
   PubMed Web of Science ®Google Scholar
• Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol. 2012;19:32–38.
   PubMed Web of Science ®Google Scholar
• Ho P, Romero S, Lew T, et al. Late onset neutropenia is a common complication of fludarabine, cyclophosphamide, and rituximab (FCR) therapy and is associated with substantial morbidity and hospitalization. 19th EHA Annual Meeting; Milan, Italy. Volume 99. Poster 53684.
   Google Scholar
• Eichhorst B, Fink AM, Busch R et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic cymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10-study) (abstract and oral presentation). 56th ASH Annual Meeting and Exposition; 2014; San Francisco, CA. Abstract 19. [cited Jun 2016]. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69485.html
   Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78–v84.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Ribakovsky E, Mizrahi N, et al. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma. 2016;57:63–69.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;37:213–223.
   Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175–1184.
   Google Scholar
• Committee for Medical Products for Human Use(CHMP). Assessment Report - Venclyxto. EMA/725631/2016. Available from: www.ema.europa.eu
   Google Scholar
• Oncologic Drugs Advisory Committee, Pediatric Subcommittee. Advisory Committee - Briefing Document: Venetoclax for the Treatment of Pediatric Patients with Relapsed/Refractory Cancers. 2016. Matter of Record (301) 890–4188. Available from: www.fda.gov
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Barrientos JC, O’Brien S, Brown JR, et al. Hematologic and immunologic function and patient well‐being for the phase III RESONATE study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. 56th ASH Annual Meeting and Exposition; 2014; San Francisco, CA. Abstract and poster 4696. [cited Jun 2016]. Available from: https://ash.confex.com/ash/2014/webprogram/Paper67774.html
   Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940–1943.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Agency EM. EMA summary of opinion (post authorisation) for Zydelig (22 July 2016). 2016:3.
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma. FDA. NCCN; Volume 4; 2014. Available from: http://www.nccn.org/guidelines/cll/files/assets/common/downloads/files/cll.pdf
   Google Scholar
• Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18:297–311.
   PubMed Web of Science ®Google Scholar
• Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4:e114–e126.
   PubMed Web of Science ®Google Scholar
• Koprulu AD, Ellmeier W. The role of Tec family kinases in mononuclear phagocytes. Crit Rev Immunol. 2009;29:317–333.
   PubMed Web of Science ®Google Scholar
• Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015;100:77–86.
   PubMed Web of Science ®Google Scholar
• Borge M, Belén Almejún M, Podaza E, et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica. 2015;100:e140–e142.
   PubMed Web of Science ®Google Scholar
• Patton DT, Garden OA, Pearce WP, et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol. 2006;177:6598–6602.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Matos T, Kim HT, et al. Idelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicities. Blood. 2015;126:497.
   Web of Science ®Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–2694.
   PubMed Web of Science ®Google Scholar
• Matos T, Lampson BL, Hirakawa M, et al. Altered expression of functional proteins in CD4 regulatory T cells during therapy with idelalisib. Blood. 2015;126:1735.
   PubMed Web of Science ®Google Scholar
• Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–2786.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1992;89:374–377.
   PubMed Web of Science ®Google Scholar
• Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35:1209–1215.
   PubMed Web of Science ®Google Scholar
• Nitzan O, Elias M, Chazan B, et al. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129–136.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis. 2005;40:990–996.
   PubMed Web of Science ®Google Scholar
• Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1487–1493.
   PubMed Web of Science ®Google Scholar
• Villafuerte-Gutierrez P, Villalon L, Losa JE, et al. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014;2014:986938.
   PubMedGoogle Scholar
• Nosari A. Infectious complications in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2012;4:e2012070.
   PubMedGoogle Scholar
• Hensel M, Kornacker M, Yammeni S, et al. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol. 2003;122:600–606.
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 2009;10:816–824.
   PubMed Web of Science ®Google Scholar
• Jouneau S, Poineuf J-S, Minjolle S, et al. Which patients should be tested for viruses on bronchoalveolar lavage fluid? Eur J Clin Microbiol Infect Dis. 2013;32:671–677.
   PubMed Web of Science ®Google Scholar
• Abbasi F. Infectious diseases and clinical complications during treatment in CLL. Oppezzo P, editor. InTech, Rijeka, Croatia; 2012. ISBN: 978-953-307-881-6.
   Google Scholar
• Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22:396–414.
   PubMed Web of Science ®Google Scholar
• Dworzack DL, Ferry JJ, Clark RB. Co-infection with Legionella pneumophila and Pneumocystis carinii in a patient with chronic lymphocytic leukemia. Nebraska Med J. 1989;74:73–75.
   PubMedGoogle Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698.
   PubMed Web of Science ®Google Scholar
• Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50:285–295.
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Carratalà J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2015;26:21–33.
   PubMed Web of Science ®Google Scholar
• Drgona L, Colita A, Klimko N, et al. Triggers for driving treatment of at-risk patients with invasive fungal disease. J Antimicrob Chemother. 2013;68(Suppl 3):iii17–iii24.
   PubMedGoogle Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Dhalla F, Lucas M, Schuh A, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol. 2014;34:277–282.
   PubMed Web of Science ®Google Scholar
• NCCN. Prevention and Treatment of cancer-related infections. Version 2.2016. Available from: https://oralcancerfoundation.org/wp-content/uploads/2016/09/infections.pdf (last Access: 24.11.2017).
   Google Scholar
• CDC. Pneumococcal Vaccination - Information for Healthcare Professionals. Centers for Disease Control and Prevention.  Available from: www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html  (last Access: 24.11.2017).
   Google Scholar
• Civan J, Hann HW. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough? Expert Opin Drug Saf. 2015;14:865–875.
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2006;132:3–12.
   PubMed Web of Science ®Google Scholar
• Pareek M, Greenaway C, Noori T, et al. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016;14:48.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Langerbains P, Busch R, Schweighofer C, et al. Severe infections are more common in physically fit CLL patients with FCR therapy compared to BR. Abstract P237. 19th EHA Annual Meeting; 2014; Milan, Italy.
   Google Scholar
• Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin’s lymphoma: a practice guide for patient management. Oncologist. 2013;18:954–964.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:452–457.
   PubMed Web of Science ®Google Scholar
• Abkur TM, Saeed M, Ahmed SZ, et al. Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol. Clin Case Rep. 2015;3:255–259.
   PubMed Web of Science ®Google Scholar
• Zydelig® Summary of Product Characteristics. Gilead. 2016 [cited 2016 Jun]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003843/WC500175377.pdf
   Google Scholar
• Cao T, Lazdina U, Desombere I, et al. Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model. J Virol. 2001;75:6359–6366.
   PubMed Web of Science ®Google Scholar
• EASL. European Association for the Study of the Liver clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
   PubMed Web of Science ®Google Scholar
• Visentin A, Compagno N, Cinetto F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100:e515–e518.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50:764–772.
   PubMed Web of Science ®Google Scholar
• Neumann S, Krause SW, Maschmeyer G, et al.; Infectious Diseases Working P, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2013;92:433–442.
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23:7024–7031.
   PubMed Web of Science ®Google Scholar
• AIDSinfo. Clinical guidelines portal. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescent. 2013 [cited 2016 Jun]. Available from: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oiprevention-and-treatment-guidelines/357/discontinuing-prophylaxis
   Google Scholar
• Singhal RL, Corman LC. Subacute herpes simplex virus type 1 encephalitis as an initial presentation of chronic lymphocytic leukemia and multiple sclerosis: a case report. J Med Case Rep. 2011;5:59.
   PubMedGoogle Scholar
• Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. Haematologica. 2016;101:1573–1580.
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832–837.
   PubMed Web of Science ®Google Scholar
• NCCN. Non-Hodgkin's lymphomas. Version 3CJ. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (last access: June 2016).
   Google Scholar
• O’Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymph Myeloma. 2006;7:125–130.
   PubMedGoogle Scholar